Varas-Lorenzo C, Castellsaque J, Stang MR, Perez-Gutthann S, Aguado J, Rodriguez LA. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1016-25.
Wolowacz S, Samuel M, Brennan VK, Jasso-Mosqueda J, van Gelder I. The cost of illness of atrial fibrillation: a systematic review. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A325.
Mauskopf J, Graham JB, Bae J, Gaich C. Impact of including prasugrel on the formulary for patients who undergo percutaneous coronary intervention for acute coronary syndrome. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A322.
Riera-Guardia N, Hirst C, Castellsague J, Varas-Lorenzo C, Pariente A, Sturkenboom MCJM, Perez-Gutthann S. The SOS project: cardiovascular and gastrointestinal safety of NSAIDS. Preliminary results of a systematic review of epidemiological studies. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug 16; 18(Suppl 1):S207.
Gilsenan A, Andrews EB, Calingaert B, Crozier DA, Vanderpuije A. Evaluation of current risk evaluation and mitigation strategies. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 16, 2009. Providence, RI.
Loughlin J, Quinn S, Rivero E, Norman H, Earnes DL, Wong J, Seeger JD. No evidence for association of tegaserod with adverse cardiovascular ischemic events. Presented at the 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug; 18(Suppl 1):S17.
Varas-Lorenzo C, Johannes C, McQuay L, Midkiff K, Stang MR, Fife D. Validation of serious ventricular arrhythmias in an administrative database. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 16, 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug; 18(S1-273):S222.
Earnshaw SR, Wilson M, Mauskopf J, Joshi AV. Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges. Value Health. 2009 Jun 1;12(4):507-20.
Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, Tang J, Krajenta R, Pladevall-Vila M, Williams LK. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):437-47. doi: 10.1002/pds.1722
Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson P, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty with moderate impairment of renal function. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 15, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A151.
Earnshaw SR, Jackson D, Farkouh R, Schwamm L. Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis. Stroke. 2009 May 1;40(5):1710-20.
Mauskopf J, Schmitt C, Boye KS, McCollam PL, Juniper MD, Birt JA. Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 21, 2009. [abstract] Value Health. 2009 May; 12(2):A148.
Greene BL, Miller JD, Brown TM, Harshman RS, Richerson GT, Doyle JJ. Economic impact of the BP DownShift Program on blood pressure control among commercial driver license employees. J Occup Environ Med. 2009 May 1;51(5):542-53.
Chen L, Candrilli SD. Age-segmented rates of treatment, goal attainment, comorbidities and lifestyle risks among men diagnosed with hypertension and dyslipidemia in the United States. Poster presented at the 2009 Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference; April 2009.
Mauskopf JA, Boye KS, Schmitt C, McCollam P, Birt J, Juniper MD, Bakhai A. Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy. J Med Econ. 2009 Jan 1;12(2):141-53.
Lundbye-Christensen S, Dethlefsen C, Gorst-Rasmussen A, Fischer T, Schønheyder HC, Rothman KJ, Sørensen HT. Examining secular trends and seasonality in count data using dynamic generalized linear modeling: a new methodological approach illustrated with hospital discharge data on myocardial infarction. Eur J Epidemiol. 2009;24(5):225-30.
Rothman KJ. Bare versus drug-eluting stents in acute myocardial infarction. N Engl J Med. 2009;360:301.
Sanders J, Hawe E, Brull DJ, Hubbart C, Lowe GD, Rumley A, Humphries SE, Montgomery HE. Higher IL-6 levels but not IL6 -174G>C or -572G>C genotype are associated with post-operative complication following coronary artery bypass graft (CABG) surgery. Atherosclerosis. 2009;204(1):196-201.
Varas-Lorenzo C, Castellsague J, Stang MR, Perez-Gutthann S, Aguado J, Rodriguez LA. The use of selective cycoxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf. 2009;18(11):1016-25.
Candrilli SD, Roberts C, Classi P. Changes in cardiovascular events and procedures from 2000-2005. Poster presented at the American Heart Association's 2008 Scientific Sessions; November 2008.
Hawe E, Baillie L, Praet C. The direct cost of atrial fibrillation to the NHS in the UK. November 2008. ed. London: United Kingdom. OHE consulting report; 2008.
Seeger JD, Loughlin J, Rivero E, Earnest DL, Quinn SG, Huang J, Rueegg P, Dennis E, Kralstein J. No evidence for association of tegaserod with cardiovascular adverse ischemic events (CVIE) in routine clinical practice. Presented at the Annual Meeting of the American College of Gastroenterology; October 2008. Orlando, FL.
Greene BL, Brown TM, Miller JD, Harshman R, Richerson G, Doyle JJ. Economic impact of the BP downshift program on blood pressure control among commercial driver license employees. Poster presented at the 2008 Academy of Managed Care Pharmacy Educational Conference; October 2008. [abstract] Am J Manag Care. 2008 Oct; 14(7).
Gilsenan AW, Ladner A, Varas-Lorenzo C, Kold Olesen T, Karup C, Andrews EB. Incidence of cardiovascular and cerebrovascular events among men with prostate cancer. Poster presented at the 24th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 9, 2008. Copenhagen, Denmark.
Jacquemin B, Antoniades C, Nyberg F, Plana E, Muller M, Greven S. Common genetic polymorphisms and haplotypes of fibrinogen alpha, beta, and gamma chains affect fibrinogen levels and the response to proinflammatory stimulation in myocardial infarction survivors: the AIRGENE study. J Am Coll Cardiol. 2008 Sep 9;52(11):941-52.
Lee E, Candrilli SD, Roberts CS, Tang SSK, Bassin S, Wong ND. Regional Differences in the Prevalence, Treatment and Control of Hypertension and Dyslipidemia in Us Urban Hispanic Populations Participating in Health Screening Events. Ethn Dis. 2008 Sep 1;18(4):409-14.
Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H, Avorn J, Sturmer T. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Care Res (Hoboken). 2008 Aug 15;59(8):1097-104.
Varas-Lorenzo C, Castellsague J, Stang MR, Tomas L, Aguado J, Perez-Gutthann S. Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database. Pharmacoepidemiol Drug Saf. 2008 Aug 1;17(8):842-52.
Varas-Lorenzo C, Castellsaque J, Stang MR, Tomas L, Aguado J, Perez-Gutthann S. Positive predictive value of icd-9 codes 410-411 for acute coronary syndromes: saskatchewan hospital automated database. Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):842-52.
Candrilli SD, Kuznik A. The prevalence and overlap of select cardiovascular co-morbidities among US adults with dyslipidemia, by lipid-lowering medication use status. Poster presented at the 2008 Midwest Social and Administrative Pharmacy Conference; July 2008. Previously presented at the Annual Meeting of the American College of Clinical Pharmacy.
Heisler M, Hogan MM, Hofer TP, Schmittdiel JA, Pladevall-Vila M, Kerr EA. When more is not better: treatment intensification among hypertensive patients with poor medication adherence. Circulation. 2008 Jun 3;117(22):2884-92. doi: 10.1161/CIRCULATIONAHA.107.724104
Umscheid CA, Maguire MG, Pines JM, Everett WW, Baren JM, Townsend RR, Mines D, Szyld D, Gross R. Untreated hypertension and the emergency department: a chance to intervene? Acad Emerg Med. 2008 Jun;15(6):529-36. doi: 10.1111/j.1553-2712.2008.00132.x
Tang SS, Candrilli SD, Shi L. Utilization of lipid-lowering therapy in hypertensive patients in the United States. Poster presented at the 2008 AcademyHealth Annual Research Meeting; June 2008.
Candrilli SD, Kuznik A. The prevalence and overlap of select cardiovascular comorbidities among dyslipidemic US adults aged 65 years or older, stratified by lipid-lowering medication use. Poster presented at the 31st Annual Meeting of the Society of General Internal Medicine; April 2008. Pittsburg, PA. [abstract] J Gen Intern Med. 2008 Apr; 23(Supplement 2):419.
Harshman RS, Richerson GT, Hadker N, Greene BL, Brown TM, Foster TS. Impact of a hypertension management/health promotion program on commercial driver's license employees of a self-insured utility company. J Occup Environ Med. 2008 Mar 1;50(3):359-65.
Coffin D, Duval K, Martel S, Granton J, Lefebvre MC, Meads DM, Twiss J, McKenna SP. Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Can Respir J. 2008 Mar;15(2):77-83.
Menzin J, Wygant G, Hauch O, Jackel JL, Friedman M. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Curr Med Res Opin. 2008 Feb;24(2):461-8. doi: 10.1185/030079908X261096 .
Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Granger AL, Fehnel SE, Levine KB, Jordan J, Clark RV. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric. 2008 Jan 1;11(1):32-43.
Adams MR, Anthony MS, Chen H, Clarkson TB. Replacement of dietary soy protein isolate with concentrates of soy 7S or 11S globulin has minimal or no effects on plasma lipoprotein profiles and biomarkers of coronary risk in monkeys. Atherosclerosis. 2008 Jan;196(1):76-80.
Zierler S, Theodore M, Cohen A, Rothman KJ. Chemical quality of maternal drinking water and congenital heart disease. Int J Epidemiol. 1988 Sep;17(3):589-94.